Roche Palo Alto LLC

I'll research this company before writing the profile.

Roche Palo Alto LLC is a wholly owned subsidiary of Roche Holdings, Inc.; its ultimate parent is Roche Holding Ltd., the Basel-based pharmaceutical group traded on the Swiss exchange (SIX: ROG). Its registered address is 3431 Hillview Avenue, Palo Alto, California. The entity traces to Syntex Corp. / Syntex (U.S.A.) LLC, the Palo Alto pharmaceutical and diagnostics company Roche acquired in 1994 and renamed Roche Bioscience in 1995 before it later took the Roche Palo Alto name. Roche confirmed in September 2008 that it would close the roughly 1-million-square-foot Palo Alto campus — then about 1,000 employees — in connection with its Genentech acquisition, relocating inflammation work to New Jersey and virology work to South San Francisco. Roche does not publish standalone headcount or revenue for this subsidiary.

Operations: The Palo Alto site was a drug-discovery and development organization focused on inflammation, viral diseases (including HCV/HIV), and related therapeutic areas. It had no independent commercial product line of its own; commercialization of relevant products runs through Roche and licensing partners such as Helsinn and Eisai.

Litigation posture: All five tracked cases are as plaintiff and none as defendant — the profile of a patent owner enforcing IP, not a defensive target or an NPE. Every tracked suit is a Hatch-Waxman action (ANDA or 505(b)(2) filings) brought jointly with Helsinn Healthcare S.A., asserting Orange Book-listed palonosetron formulation patents covering Aloxi (palonosetron HCl injection). Venues are D.N.J. and D. Delaware, not the Eastern District of Texas.

Notable cases: Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories (D.N.J., 2011); v. Cipla (D. Del., 2013); v. Mylan Institutional (D. Del., 2014); and v. Hospira (D. Del., 2015), plus an untitled 2013 D. Del. case. Roche Palo Alto is a co-assignee on patents in the family, including U.S. 7,947,724; 7,947,725; 7,960,424; 8,518,981; 8,598,219; and 8,729,094. In the Teva appeal (Fed. Cir. 2016-1284), Roche Palo Alto assigned its rights in the appealed patents to Helsinn and withdrew as a party; the Federal Circuit later reversed the district court's judgment. Patent-office records list continued Roche Palo Alto assignment activity in later years.